Recombinant erythropoietin trial in children with transfusion-dependent homozygous β-Thalassemia

Acta Haematologica

Volumn 98, Issue 4, 1997, Pages 199-203

  Nisli, Güngör ^a   Kavakli, Kaan ^a   Aydinok, Yesim ^a   Öztop, Senay ^a   Çetingül, Nazan ^a   Basakh, Nazli ^b  

^a EGE UNIVERSITY   (Turkey)

^b BOGAZICI UNIVERSITY   (Turkey)

Author keywords

Erythropoiesis; Erythropoietin; Recombinant; Thalassemia major

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; FERRITIN; HEMOGLOBIN; HEMOGLOBIN F; IRON; RECOMBINANT ERYTHROPOIETIN; UREA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA THALASSEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; GENOTYPE; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION PAIN; IRON THERAPY; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETICULOCYTE; RETICULOCYTE COUNT; SPLENECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 0030806562     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203624     Document Type: Article

References (34)

1. Cavdar AO, Arcasoy A: The incidence of beta thalassemia and abnormal hemoglobin in Turkey. Acta Hematol 1971;45:312-318.
2. Akar N, Qtvdar AO, Dessi E, Loi A, Pirasta M, Cao A: Beta thalassemia mutations in Turkish population. J Med Genet 1987;24:378-382.
3. Oner R, Altay Q, Giirgey A, Aksoy M, Kiltnf Y, Stoming TA, Reese AL, Kutlar A, Kutlar F, Huisman THJ: p-Thalassemia in Turkey. Hemoglobin 1990;14:1-10.
4. Besa EC: Globin synthesis and the thalassemia syndromes; in Besa AC, Catalano PM, Kant JA, Jefferies LC (eds): Hematology. Media, Harwal, 1992, pp 115-122.
5. Davies SC, Wonke B: The management of hemoglobinopathies. Baillieres Clin Haematol 1991;4:361-389.
6. Hoffbrand AV, Pettit JE: Essential Haematology, cd 3. London, Blackwell, 1993.
7. Leg TS, DeSimone J, Anagnou NP, Keller GH: 5-Azacytidine selectively increases gamma globin synthesis in a patient with beta (+) thalassemia. N Engl J Med 1982;307:1469-1475.
8. Letvin NL, Linch DC, Beardsley P, McIntyre KW, Nathan DG: Augmentation of fetal hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984;310:869-873.
9. Galanello R, Stamatoyannopoulos G, Pa-payannopoulou T: Mechanism of Hb-F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacyti-dine, Ara-C or hydroxyurea. J Clin Invest 1988;81:1209-1216.
10. Veith R, Papayannopoulou T, Kurachi S, Stamatoyannopoulos G: Treatment of baboon with vinblastine: Insights into the mechanism of pharmacologic stimulation of Hb F in the adult. Blood 1985;66:456-459.
11. Leroy-Viard K, Rouyer-Fossard P, Beuzard Y: Improvement of mouse beta thalassemia by recombinant human erythropoietin. Blood 1991;78:1596-1602.
12. Said AA, Yamaguchi T, Uchido E, Hayakawa T: Characterization of haemolysis resistant cells increased in the blood of erythropoietin-treated mice. Br J Haematol 1994:86:36 -365.
13. Rachmilewitz EA, Goldfarb A, Dover G: Administration of erythropoietin to the patients with beta thalassemia intermedia. A preliminary trial. Blood 1991;78:1145-1147.
14. Olivieri NF, Freedman MH, Perrine SP, Dover GJ, Sheridan B, Essentine DL, Nagel R: Trial of recombinant human erythropoietin: Three patients with thalassemia intermedia. Blood 1992;80:3258-3260.
15. Cozma G, Momen AK, Hazmi MAF, Politis C, Poisson D, Nisli G: Beneficial effects of r-HU-EPO in sickle cell disease and beta thalassemia: Intermin report. Erythropoiesis 1995;6:22.
16. Nisli G, Kavakli K, Vergin C, Öztop S, Cctin-giil N: Recombinant human erythropoietin trial in thalassemia intermedia. J Trop Pediatr, in press.
17. Nisli G, Kavakli K, Öztop S, Cctingül N: Recombinant erythropoietin therapy in beta thalassemia major (abstract). Turk J Haematol 1995;14(suppl 1):275.
18. Betke K, Marti HR, Schlicht I: Estimation of small percentages of foetal hemoglobin. Nature 1959; 184:1877.
19. Kleihauer E, Braun H, Betke K: Demonstration von fetalem Hämoglobin in den Erythrozyten eines Blutabstrichs. Klin Wochenschr 1957;35:637.
20. Andre M, Ferster A, Toppet M, Fondu P. Drat-wa M, Bergmann P: Performance of an immu-noradiometric assay of erythropoietin and results for specimen from anemic and polycythemic patients. Clin Chem 1992;38:758-763.
21. Gastaldello K, Fremans W, Vanherweghem JL, Tielemans C: Current therapeutic applications of rHu EPO in anemia in chronic renal failure. Erythropoiesis 1994;5:82-87.
22. Erslev AJ: Recombinant human erythropoietin (rHu EPO) therapy in nonrenal anemia. Erythropoiesis 1994;5:69-76.
23. Olivieri NF, Sher GD, Portwine C, Ali MAM, Mac Kinnon J, Brittenham GM, Sheridan BL: Long term therapy with r-Hu EPO in patients with homozygous beta thalassemia. Erythropoiesis 1995;6:21-23.
24. De Simone J, Biel M, Heiter P: Maintenance of fetal hemoglobin (HbF) elevations in the baboon by prolonged erythropoietic stress. Blood 1982;60:519-523.
25. Cynshi O, Satoh K, Higushi M, Imai N: Effects of rHu EPO on anaemic W/Wv and SI/SId mice. BrJ Haematol 1990;75:319-324.
26. Stamatoyannopoulos G, Veith R, Al-Khatti A, Fritsh EF, Goldwasser E, Papayannopoulou T: On the induction of fetal hemoglobin in adult; stress erythropoiesis, cell cycle-specific drugs, and recombinant erythropoietin; in Stamatoyannopoulos G (ed): Developmental Control of Globin Gene. New York, Liss, 1987, pp 443-453.
27. Koury MJ, Bondurant MC: The maintenance by erythropoietin of viability, proliferation and maturation of murine erythroid precursor cells. J Cell Physiol 1988;137:65-74.
28. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-381.
29. Muta K, Kruntz S: Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor-1 as well as erythropoietin. J Cell Physiol 1993; 156:264-271.
30. Yu H, Bauer G, Lipkc GK, Philips RL, Van-Zant G: Apoptosis and hematopoiesis in murine fetal liver. Blood 1993;81:373-384.
31. Bondurant M, Kelley L, Koury M: Is erythropoietin a differentiation factor, amitotic factor, ora survival factor? In BaverC, Koch KM, Sci-galla P, Wieczorek L (eds): Erythropoietin, Molecular Physiology and Clinical Applications. New York, Dekker, 1994, pp 241-253.
32. Koury M: Progress in understanding erythropoiesis; in Smyth JF, Boognerts MA, Ehmer BRM (eds): r-Hu-Erythropoietin in Cancer Supportive Treatment. New York, Dekker, 1996, pp 1-12.
33. Gringras P, Wonke B, Old J, Fitches A, Valler D, Kuan AM, Hoffbrand AV: Effect of alpha thalassemia trait and enhanced gamma chain production on disease severity in beta thalassemia major and intermedia. Arch Dis Child 1994;70:30-34.
34. Aker M, Perry D, Dover G, Rachmilewitz EA: The effect of combined rHu EPO and hydroxyurea of erythropoiesis in beta thalassemia intermedia. Turk J Haematol 1995;14(suppl 1): 210.